Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 19;10(2):364.
doi: 10.3390/jcm10020364.

Dermatological Manifestations in Inflammatory Bowel Diseases

Affiliations
Review

Dermatological Manifestations in Inflammatory Bowel Diseases

Elisabetta Antonelli et al. J Clin Med. .

Abstract

Inflammatory bowel diseases (IBDs) may be associated with extra-intestinal manifestations. Among these, mucocutaneous manifestations are relatively frequent, often difficult to diagnose and treat, and may complicate the course of the underlying disease. In the present review, a summary of the most relevant literature on the dermatologic manifestations occurring in patients with inflammatory bowel diseases has been reviewed. The following dermatological manifestations associated with IBDs have been identified: (i) specific manifestations with the same histological features of the underlying IBD (occurring only in Crohn's disease); (ii) cutaneous disorders associated with IBDs (such as aphthous stomatitis, erythema nodosum, psoriasis, epidermolysis bullosa acquisita); (iii) reactive mucocutaneous manifestations of IBDs (such as pyoderma gangrenosum, Sweet's syndrome, bowel-associated dermatosis-arthritis syndrome, aseptic abscess ulcers, pyodermatitis-pyostomatitis vegetans, etc.); (iv) mucocutaneous conditions secondary to treatment (including injection site reactions, infusion reactions, paradoxical reactions, eczematous and psoriasis-like reactions, cutaneous infections, and cutaneous malignancies); (v) manifestations due to nutritional malabsorption (such as stomatitis, glossitis, angular cheilitis, pellagra, scurvy, purpura, acrodermatitis enteropathica, phrynoderma, seborrheic-type dermatitis, hair and nail abnormalities). An accurate dermatological examination is essential in all IBD patients, especially in candidates to biologic therapies, in whom drug-induced cutaneous reactions may assume marked clinical relevance.

Keywords: Crohn’s disease; dermatological manifestations; inflammatory bowel disease; skin; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mucocutaneous manifestations associated with inflammatory bowel disease (IBD).
Figure 2
Figure 2
Erythematous plaque on the inner aspect of the right thigh of a patient with cutaneous Crohn’s disease.
Figure 3
Figure 3
Aphthous stomatitis in a patient with Crohn’s disease.
Figure 4
Figure 4
Erythematous nodules on the calves of a patient with ulcerative colitis-related erythema nodosum.
Figure 5
Figure 5
Ulcerative lesion with irregular violaceous, undermined borders on the right thigh of a patient with ulcerative colitis-associated pyoderma gangrenosum.
Figure 6
Figure 6
Erythematous papulonodular lesions involving the face of a patient with Sweet’s syndrome associated with Crohn’s disease.
Figure 7
Figure 7
Vegetating plaques localized on the beard region of a patient with ulcerative colitis-associated pyodermatitis vegetans.
Figure 8
Figure 8
Erythematous-edematous reaction involving the injection site of etanercept in the left thigh.
Figure 9
Figure 9
Psoriasiform eruption involving the abdomen and the pubic area of a patient undergoing adalimumab treatment.
Figure 10
Figure 10
Proposed algorithm for psoriasis management in IBD.

Comment in

References

    1. Harbord M., Annese V., Vavricka S.R., Allez M., Acosta M.B.-D., Boberg K.M., Burisch J., De Vos M., De Vries A.-M., Dick A.D., et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J. Crohn’s Colitis. 2016;10:239–254. doi: 10.1093/ecco-jcc/jjv213. - DOI - PMC - PubMed
    1. Vavricka S.R., Brun L., Ballabeni P., Pittet V., Vavricka B.M.P., Zeitz J., Rogler G., Schoepfer A.M. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease Cohort. Am. J. Gastroenterol. 2011;106:110–119. doi: 10.1038/ajg.2010.343. - DOI - PubMed
    1. Rankin G.B., Watts H.D., Melnyk C.S., Kelley M.L., Jr. National cooperative Crohn’s disease study: Extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–920. doi: 10.1016/0016-5085(79)90391-3. - DOI - PubMed
    1. Veloso F.T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J. Clin. Gastroenterol. 1996;23:29–34. doi: 10.1097/00004836-199607000-00009. - DOI - PubMed
    1. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am. J. Gastroenterol. 2001;96:1116–1122. doi: 10.1111/j.1572-0241.2001.03756.x. - DOI - PubMed